IDEX Corporation earnings overview

IEX FY2026 Q1 · Calendar Q2 2026

IDEX Corporation

IDEX's Q1 FY2026 results mark an inflection from the modest 1-2% organic growth outlook maintained just one quarter ago. The Health & Science Technologies segment is the primary engine, with 17% organic order growth driven by AI-related data-center, semiconductor, and space-and-defense demand. A backlog build in HST now gives management visibility into growth through 2027, which supports the decision to raise full-year guidance to 3-4% organic growth and lift adjusted EPS to $8.35-$8.55. The 8020 strategic framework continues to deliver margin leverage, with adjusted EBITDA margin expanding 50 bps to 26%. While short-cycle industrial markets in FMT and FSDP remain soft, the divergence between high-growth HST and sluggish industrial segments is widening, and management is redirecting capital and CapEx toward HST capacity to capture that growth.